These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25550394)

  • 1. Emergence of multiple resistance profiles involving azoles, echinocandins and amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia.
    Cho EJ; Shin JH; Kim SH; Kim HK; Park JS; Sung H; Kim MN; Im HJ
    J Antimicrob Chemother; 2015 Apr; 70(4):1268-70. PubMed ID: 25550394
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.
    Denardi LB; Keller JT; Oliveira V; Mario DAN; Santurio JM; Alves SH
    Mycopathologia; 2017 Oct; 182(9-10):819-828. PubMed ID: 28493006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.
    Bizerra FC; Jimenez-Ortigosa C; Souza AC; Breda GL; Queiroz-Telles F; Perlin DS; Colombo AL
    Antimicrob Agents Chemother; 2014; 58(4):2438-40. PubMed ID: 24468776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
    Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH
    Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait.
    Al-Baqsami ZF; Ahmad S; Khan Z
    Sci Rep; 2020 Apr; 10(1):6238. PubMed ID: 32277126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
    Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
    Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
    Pfaller MA; Castanheira M; Lockhart SR; Ahlquist AM; Messer SA; Jones RN
    J Clin Microbiol; 2012 Apr; 50(4):1199-203. PubMed ID: 22278842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
    Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
    Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mating genotypes and susceptibility profiles of clinical isolates of Candida glabrata from Turkey.
    Kaplan E; Aktaş D; Önder Ş; Metin B; Döğen A; Oz Y; Ilkit M
    Mycoses; 2019 Sep; 62(9):796-802. PubMed ID: 31134666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.
    Krogh-Madsen M; Arendrup MC; Heslet L; Knudsen JD
    Clin Infect Dis; 2006 Apr; 42(7):938-44. PubMed ID: 16511756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.
    Beyda ND; Liao G; Endres BT; Lewis RE; Garey KW
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5405-12. PubMed ID: 26100700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.
    Nagappan V; Boikov D; Vazquez JA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):522-5. PubMed ID: 19841143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of azole resistance among clinical isolates of Candida glabrata in Poland.
    Szweda P; Gucwa K; Romanowska E; Dzierz Anowska-Fangrat K; Naumiuk Ł; Brillowska-Da Browska A; Wojciechowska-Koszko I; Milewski S
    J Med Microbiol; 2015 Jun; 64(6):610-619. PubMed ID: 25818698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Case of candidemia with Candida glabrata with confirmation of the acquisition of micafungin sensitivity due to new mutation of FKS gene mutation].
    Saraya T; Watanabe T; Tsujimoto N; Takata S; Araki K; Makino H; Yonetani S; Takizawa H; Goto H
    Kansenshogaku Zasshi; 2014 May; 88(3 Suppl 9-10):1-5. PubMed ID: 25033496
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC.
    Saraya T; Tanabe K; Araki K; Yonetani S; Makino H; Watanabe T; Tsujimoto N; Takata S; Kurai D; Ishii H; Miyazaki Y; Takizawa H; Goto H
    J Clin Microbiol; 2014 Jul; 52(7):2709-12. PubMed ID: 24789192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.
    Lewis JS; Wiederhold NP; Wickes BL; Patterson TF; Jorgensen JH
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4559-61. PubMed ID: 23817368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods.
    Kiraz N; Dag I; Yamac M; Kiremitci A; Kasifoglu N; Akgun Y
    Antimicrob Agents Chemother; 2009 Feb; 53(2):788-90. PubMed ID: 19029317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.